Insider Transactions in Q1 2021 at Monopar Therapeutics (MNPR)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+19.81%
|
-
|
|
Mar 31
2021
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+0.35%
|
-
|
|
Mar 31
2021
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+9.64%
|
-
|
|
Mar 31
2021
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+26.91%
|
-
|
|
Feb 11
2021
|
Tactic Pharma LLC |
SELL
Open market or private sale
|
Direct |
125,000
-10.54%
|
$1,875,000
$15.17 P/Share
|
|
Jan 01
2021
|
Andrew Paul Mazar Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
671
-4.21%
|
$4,026
$6.12 P/Share
|
|
Jan 01
2021
|
Andrew Paul Mazar Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,937
+10.84%
|
-
|
|
Jan 01
2021
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,327
-11.23%
|
$13,962
$6.12 P/Share
|
|
Jan 01
2021
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,724
+24.5%
|
-
|
|
Jan 01
2021
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
504
-32.39%
|
$3,024
$6.12 P/Share
|
|
Jan 01
2021
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,231
+44.17%
|
-
|